Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.

MLA

Abdul-Rahim, Azmil H., et al. “Efficacy and Safety of Digoxin in Patients with Heart Failure and Reduced Ejection Fraction According to Diabetes Status: An Analysis of the Digitalis Investigation Group (DIG) Trial.” International Journal of Cardiology, vol. 209, Apr. 2016, pp. 310–16. EBSCOhost, https://doi.org/10.1016/j.ijcard.2016.02.074.

APA

Abdul-Rahim, A. H., MacIsaac, R. L., Jhund, P. S., Petrie, M. C., Lees, K. R., & McMurray, J. J. V. (2016). Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 209, 310–316. https://doi.org/10.1016/j.ijcard.2016.02.074

Chicago

Abdul-Rahim, Azmil H., Rachael L. MacIsaac, Pardeep S. Jhund, Mark C. Petrie, Kennedy R. Lees, and John J.V. McMurray. 2016. “Efficacy and Safety of Digoxin in Patients with Heart Failure and Reduced Ejection Fraction According to Diabetes Status: An Analysis of the Digitalis Investigation Group (DIG) Trial.” International Journal of Cardiology 209 (April): 310–16. doi:10.1016/j.ijcard.2016.02.074.